**Mizzou BioJoint® Osteochondral Allograft Transplantation**

Osteochondral allograft (OCA) transplantation in the knee has been performed for more than 40 years in the US and Canada. The vast majority of these surgeries involve one area of the knee (unipolar) with much fewer done to treat multiple areas of the knee (bipolar). In all reported studies, unipolar surgeries have had far better outcomes than bipolar surgeries as summarized below.

Summary of 40+ years of historical data for OCA transplantation in the knee performed at other centers around the world:

- 5-year functional survival: 64-100%
- 10-year functional survival: 39-93%
- 15-year functional survival: 56-84%
- 20-year functional survival: 66-69%
- Need for revision: 30.2%
  - Unipolar: 0-63%
  - Bipolar: 39-100%
- Need for total joint replacement: 18.2%
  - Unipolar: 8-24%
  - Bipolar: 39-100%


The following statistics are for knee surgeries performed at the Mizzou BioJoint® Center using MOPSSM grafts:

- 1-year functional survival: 92%
- 2-year functional survival: 89%
- 3-year functional survival: 89%
- 5, 10, 15 and 20-year functional survival: UNKNOWN
- Need for revision: 5%
  - Unipolar: 2%
  - Bipolar: 7%
- Need for traditional joint replacement: 11%
  - Unipolar: 2%
  - Bipolar: 16%


*The vast majority of the scientific evidence for osteochondral allograft transplantation worldwide and at The Mizzou BioJoint® Center has been for treatment of the knee. Hip, ankle, and shoulder osteochondral allografts are performed less commonly.

**Statistics are based on primary osteochondral allograft transplantations in the knee performed at the Mizzou BioJoint® Center using MOPSSM-preserved grafts; these statistics do not include surgeries performed at the Mizzou BioJoint® Center to revise previous osteochondral allograft transplants or previous total or partial joint replacements. Outcomes for these special revision cases in the knee and for hip, ankle and shoulder osteochondral allograft transplants can be provided during consultation with our physicians or scientific director.

***Osteochondral allograft transplantations at the Mizzou BioJoint® Center using MOPSSM grafts began in January 2016. Outcomes data are regularly updated as longer term outcomes become available.